登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Glypican 3 >GP3-HF2H1

FITC-Labeled Human Glypican 3 / GPC3 Protein, His Tag

分子别名(Synonym)

GPC3,OCI5,Glypican-3,GTR2-2,MXR7,DGSX,SDYS ,SGB,SGBS,SGBS1

表达区间及表达系统(Source)

FITC-Labeled Human Glypican 3, His Tag (Cat. No. GP3-HF2H1) is expressed from human HEK293 cells. It contains AA Gln 25 - His 559 (Accession # P51654-1). It is the FITC labeled form of Human Glypican 3, His Tag (Cat. No. GP3-H52H4).

Predicted N-terminus: Gln 25 & Ser 359

Request for sequence

蛋白结构(Molecular Characterization)

Glypican 3 Structure

This protein carries a polyhistidine tag at the C-terminus.

This protein contains a furin-like convertase cleavage site, 355-RQYR-358, and will be partially processed into N and C-terminal fragment with calculated MW of 38.1 kDa and 24.6 kDa respectively. The protein migrates as 30 kDa, 38-40 kDa, and 65-90 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

偶联(Conjugate)

FITC

Excitation source: 488 nm spectral line, argon-ion laser

Excitation Wavelength: 488 nm

Emission Wavelength: 535 nm

标记(Labeling)

The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.

蛋白标记度(Protein Ratio)

The FITC to protein molar ratio is 3.5-6.5.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Glypican 3 SDS-PAGE

FITC-Labeled Human Glypican 3, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

 

活性(Bioactivity)-ELISA

Glypican 3 ELISA

Immobilized Anti-hGPC3 antibody (Human IgG1) at 10 μg/mL (100 μL/well) can bind FITC-Labeled Human Glypican 3, His Tag (Cat. No. GP3-HF2H1) with a linear range of 0.078-0.625 μg/mL (QC tested).

Protocol

 

CAR阳性表达率检测(Evaluation of CAR expression)

FACS Analysis of anti-GPC3 CAR Expression

Glypican 3 CAR_T

293 cells were transfected with anti-GPC3-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human Glypican 3, His Tag (Cat. No. GP3-HF2H1, 3 µg/ml) and C. FITC-labeled Protein Control. A. Non-transfected 293 cells and C. FITC-labeled Protein Control were used as negative control. RFP was used to evaluate CAR (anti-GPC3-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human Glypican 3, His Tag (Cat. No. GP3-HF2H1) (QC tested).

 

背景(Background)

Glypican-3 (GPC3) is also known as Intestinal protein OCI-5, GTR2-2, MXR7, which belongs to the glypican family. Glypican 3 / GPC-3 is highly expressed in lung, liver and kidney. Glypican-3 inhibits the dipeptidyl peptidase activity of DPP4. Glypican-3 may be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs, and also may play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Glypican 3靶点信息
英文全称:Glypican-3
中文全称:磷脂酰肌醇聚糖3
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:31详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定